Vaxil Bio is a cutting-edge Israeli biotech focused on immuno-oncology as innovative cancer treatments. Vaxil's lead product, Immucin, has recently been granted "Orphan Drug Status" from both the FDA and the EMA agencies. Vaxil is based out of the Weizmann Science Park, Israel's top scientific institution, and was founded by Weizmann PhD Dr. Lior Carmon. The Company has completed a highly successful Phase-I/II in 15 Mutiple Myeloma patients, wherein 100% demonstrated robust immune responses, the results of which were published in the British Journal of Haematology Vaxil's patented platform, VaxHit, will protect the Company's ability to develop further cancer immunotherapy products utilizing the signal peptide domain of MUC1 which is present in 90% of cancers. Please visit www.vaxil-bio.com for more information